News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas (Full text available)


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.kluweronline.com/issn/0167-594X

Posted on: 09/16/2004

Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas

[Click on link above for free full text access!]

Journal of Neuro-Oncology
65 (3): 203-226, December 2003
Copyright © 2003 Kluwer Academic Publishers
All rights reserved


Amish C. Shah
Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama, USA
Dale Benos
Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama, USA
G. Yancey Gillespie
Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
James M. Markert
Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Surgery, Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA


Abstract
Gene therapy using viral vectors for the treatment of primary brain tumors has proven to be a promising novel treatment modality. Much effort in the past has been placed in utilizing replication-defective viruses to this end but they have shown many disadvantages. Much recent attention has been focused on the potential of replication-competent viruses to discriminatingly target, replicate within, and destroy tumor cells via oncolysis, leaving adjacent post-mitotic neurons unharmed. The engineered tumor-selective herpes simplex-1 virus (HSV-1) mutants G207 and HSV1716 have completed Phase I investigations in the treatment of recurrent high-grade glioma. The results of these clinical trials are reviewed here. This review also aims to examine the manipulation and development of other viruses for the treatment of malignant glioma, including Newcastle disease virus, reovirus, poliovirus, vaccinia virus, and adenoviruses, in particular the adenovirus mutant ONYX-015.

Keywords
clinical trials, G207, gene therapy, HSV 1716, malignant glioma, newcastle disease virus, oncolytic, ONYX-015 adenovirus, poliovirus replicon, reovirus, vaccinia
Article ID: 5139199



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740